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Patients with peripheral arterial disease have a major impair-
ment in exercise performance, physical functioning, and quality of
life. This severe limitation has now been recognized to affect not
only patients with classic symptoms of intermittent claudication
but also patients with peripheral arterial disease who have atypical
symptoms or are even asymptomatic. Thus, it is the presence of
arterial occlusive disease in the lower extremity, and not just
claudication per se, that is associated with physical impairments.
The pathophysiology of claudication is complex and not sim-
ply related to hemodynamic flow limitations. Although muscle
ischemia with exercise is the primary pathophysiology, there are
secondary sequelae of intermittent episodes of ischemia with walk-
ing that lead to further limitations in function. Previously de-
scribed are alterations in skeletal muscle oxidative metabolism and
mitochondrial function, physical inactivity with deconditioning,
and altered biomechanics of walking.
In this context, the article by Gardner et al provides important
new information about the role of metabolic syndrome on contrib-
uting to functional limitations in patients with claudication. These
authors evaluated patients with claudication with and without the
metabolic syndrome. Those with metabolic syndrome had signifi-
cantly worse treadmill exercise performance, measures of quality of
life, and reductions in calf blood flow compared with those patients
with claudication who did not have metabolic syndrome. These
observations provide new and important information about addi-
tional major contributors to reduced performance, with a meta-
bolic underpinning. These observations are consistent with previ-
ous reports demonstrating alterations of skeletal muscle
metabolism in patients with claudication.
What remains unclear is the role of treating these risk factors in
terms of improving performance. However, other studies have
shown that medications such as statins may improve exercise
performance independent of alterations in blood flow. The critical
message from the Gardner et al study is to focus on the compre-
hensive management of patients with claudication and recognize
that their physical impairments are not simply a manifestation of
their lower-extremity arterial occlusive disease but also include
several other components that are amenable to therapy.
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